Galectins in the tumor endothelium: opportunities for combined cancer therapy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Galectins are emerging as a family of proteins that play an important role in several steps of tumorigenesis. Evidence is accumulating that galectins are expressed by the tumor endothelium, where they contribute to different steps of tumor progression such as immune escape and metastasis. Recent studies have identified an important role for galectins in tumor angiogenesis. Moreover, it has been shown that galectins in the endothelium can be targeted for therapeutic applications. This opens a window of opportunity for the development of tumor-type independent treatment strategies. This review focuses on the expression of galectins in the tumor endothelium, their contribution to tumor progression, and their application in tumor-type independent cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
β1-6 Branching of Asn-Linked Oligosaccharides Is Directly Associated with Metastasis
Dennis, J. W., Laferté, S., Waghorne, C., Breitman, M. L., & Kerbel, R. S. (1987) · Science · doi:10.1126/science.2953071 · Cited by 940
Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
Demetriou, M., Granovsky, M., Quaggin, S., & Dennis, J. W. (2001) · Nature · doi:10.1038/35055582 · Cited by 901
A highly conserved tyrosine of Tim‐3 is phosphorylated upon stimulation by its ligand galectin‐9
van de Weyer, P. S., Muehlfeit, M., Klose, C., Bonventre, J. V., Walz, G., & Kuehn, E. W. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.079 · Cited by 198
Cited by
Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation
Rabinovich, G. A., & Toscano, M. A. (2009) · Nature Reviews Immunology · doi:10.1038/nri2536 · Cited by 904
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells
Gieseke, F., Böhringer, J., Bussolari, R., Dominici, M., Handgretinger, R., & Müller, I. (2010) · Blood · doi:10.1182/blood-2010-02-270777 · Cited by 265
Ambekar, A. S., Nirujogi, R. S., Srikanth, S. M., Chavan, S., Kelkar, D. S., Hinduja, I., Zaveri, K., Prasad, T. S. K., Harsha, H. C., Pandey, A., et al. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.05.017 · Cited by 164
Grubb, S. E. W., Murdoch, C., Sudbery, P. E., Saville, S. P., Lopez-Ribot, J. L., & Thornhill, M. H. (2008) · Infection and Immunity · doi:10.1128/iai.00332-08 · Cited by 87
Metadata
- Authors
- Thijssen, V. L. J. L., Poirier, F., Baum, L. G., & Griffioen, A. W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-10-15
- Volume
- 110
- Issue
- 8
- Pages
- 2819-2827
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2057283587
- Cited by
- 132
- References
- 4
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectins in the tumor endothelium: opportunities for combined cancer therapy. https://app.cochat.ai/papers/10.1182/blood-2007-03-077792
- The paper
- Thijssen, V. L. J. L., Poirier, F., Baum, L. G., & Griffioen, A. W. (2007). Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood. https://doi.org/10.1182/blood-2007-03-077792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.